Comparison · NCT01715896-sae
Golimumab 50 mg Alternating With Placebo vs Mavrilimumab 100 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Golimumab 50 mg Alternating With Placebo vs Mavrilimumab 100 mg: serious adverse events. Trial comparisons, record NCT01715896-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01715896-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0441 | 0.0151 | 0.122 | wilson | |
| Risk in group 2 | 0.0286 | 0.00787 | 0.0983 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0155 | -0.06 | 0.096 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.54 | 0.266 | 8.96 | log | |
| Odds ratio, group 1 over group 2 | 1.57 | 0.254 | 9.7 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Golimumab 50 mg Alternating With Placebo than on Mavrilimumab 100 mg | 64.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Golimumab 50 mg Alternating With Placebo | Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route. | 3 | 68 | EG000 |
| Group 2 | Mavrilimumab 100 mg | Participants received mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route. | 2 | 70 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to Day 169
Source ClinicalTrials.gov
Trial
- Title
- A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
- NCT number
- NCT01715896
- Phases
- PHASE2
- Conditions
- Rheumatoid Arthritis
- Interventions
- Golimumab 50 mg, Mavrilimumab 100 mg
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2016-10-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01715896?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01715896-sae